Pfizer Halts China Vaccine Sales Due To License Expiry
This article was originally published in PharmAsia News
The largest foreign drug maker in the country has had to stop marketing its best-selling vaccine Prevenar, dealing a blow to a plan to bolster its vaccine portfolio.
You may also be interested in...
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.